Regeneron Pharmaceuticals (REGN) Total Debt (2020 - 2025)
Regeneron Pharmaceuticals has reported Total Debt over the past 6 years, most recently at $2.0 billion for Q4 2025.
- Quarterly results put Total Debt at $2.0 billion for Q4 2025, changed 0.08% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (changed 0.08% YoY), and the annual figure for FY2025 was $2.0 billion, changed 0.08%.
- Total Debt for Q4 2025 was $2.0 billion at Regeneron Pharmaceuticals, roughly flat from $2.0 billion in the prior quarter.
- Over the last five years, Total Debt for REGN hit a ceiling of $2.0 billion in Q3 2025 and a floor of $2.0 billion in Q1 2021.
- Median Total Debt over the past 5 years was $2.0 billion (2023), compared with a mean of $2.0 billion.
- Peak annual rise in Total Debt hit 31.95% in 2021, while the deepest fall reached 0.07% in 2021.
- Regeneron Pharmaceuticals' Total Debt stood at $2.0 billion in 2021, then rose by 0.07% to $2.0 billion in 2022, then grew by 0.08% to $2.0 billion in 2023, then increased by 0.08% to $2.0 billion in 2024, then rose by 0.08% to $2.0 billion in 2025.
- The last three reported values for Total Debt were $2.0 billion (Q4 2025), $2.0 billion (Q3 2025), and $2.0 billion (Q2 2025) per Business Quant data.